Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression
Publication
, Journal Article
Jackson, DO; Peace, KM; Hale, DF; Vreeland, TJ; Choy, G; Nejadnik, B; Greene, JM; Schneble, EJ; Berry, JS; Trappey, AF; Hardin, MO; Holmes, JP ...
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi366
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Jackson, D. O., Peace, K. M., Hale, D. F., Vreeland, T. J., Choy, G., Nejadnik, B., … Peoples, G. E. (2016). Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology, 27, vi366. https://doi.org/10.1093/annonc/mdw378.23
Jackson, D. O., K. M. Peace, D. F. Hale, T. J. Vreeland, G. Choy, B. Nejadnik, J. M. Greene, et al. “Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression.” Annals of Oncology 27 (October 1, 2016): vi366. https://doi.org/10.1093/annonc/mdw378.23.
Jackson DO, Peace KM, Hale DF, Vreeland TJ, Choy G, Nejadnik B, et al. Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology. 2016 Oct 1;27:vi366.
Jackson, D. O., et al. “Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression.” Annals of Oncology, vol. 27, Oct. 2016, p. vi366. Scopus, doi:10.1093/annonc/mdw378.23.
Jackson DO, Peace KM, Hale DF, Vreeland TJ, Choy G, Nejadnik B, Greene JM, Schneble EJ, Berry JS, Trappey AF, Hardin MO, Clifton GT, Herbert GS, Mittendorf E, Holmes JP, Peoples GE. Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology. 2016 Oct 1;27:vi366.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi366
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis